← Back to Clinical Trials
Recruiting NCT07546903

NCT07546903 Comparison of Analgesic Efficacy of Suprainguinal Fascia Iliaca and Quadro-iliac Blocks in Hip Fracture Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07546903
Status Recruiting
Phase
Sponsor Hitit University
Condition Post Operative Pain
Study Type OBSERVATIONAL
Enrollment 70 participants
Start Date 2025-10-20
Primary Completion 2026-04-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Suprainguinal Fascia Iliaca BlockQuadro-Iliac Plane Block

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 70 participants in total. It began in 2025-10-20 with a primary completion date of 2026-04-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Hip fractures are common in the elderly and are associated with significant morbidity and mortality. Effective early analgesia is crucial for facilitating mobilization, reducing pulmonary complications, and improving overall outcomes. Although opioids are traditionally used for postoperative pain management, their adverse effects have led to increased interest in multimodal analgesia, particularly peripheral nerve blocks. The suprainguinal fascia iliaca block (SIFI) is a modified technique that allows wider spread of local anesthetic, providing more effective blockade of the femoral, obturator, and lateral femoral cutaneous nerves. The quadro-iliac plane block (QIPB), a recently described interfascial block, is performed at the level of the anterior superior iliac spine and may also affect branches of the lumbar and sacral plexus. While both techniques have been shown to provide effective analgesia and reduce opioid consumption, there is no study directly comparing them. Therefore, this study aims to compare the postoperative analgesic efficacy of SIFI and QIPB in patients undergoing hip fracture surgery.

Eligibility Criteria

Inclusion Criteria: * Patients aged 18 years and older * ASA physical status I-III * Hemodynamically stable patients * Scheduled for surgical treatment of hip fracture * Body mass index (BMI) ≤ 35 kg/m² * Provided written informed consent Exclusion Criteria: * Refusal to participate * ASA physical status IV-V * Hemodynamically unstable patients * Surgery not completed as planned * Infection at the block site * History of allergy to local anesthetics or tramadol * Presence of neuromuscular or peripheral nerve diseases * Chronic pain conditions * Coagulopathy or ongoing anticoagulant therapy * High-dose opioid use within the last 3 days * Severe hepatic or renal insufficiency * Diabetes mellitus * Pregnancy or breastfeeding * NRS score \>7 for four consecutive hours despite multimodal analgesia * Inability to understand or use assessment tools (e.g., NRS, QoR-15) * Inability to communicate in Turkish * Inability to use PCA device due to technical reasons

Contact & Investigator

Central Contact

MUHAMMED ATICI

✉ dr.matc92@gmail.com

📞 +905535716152

Principal Investigator

Ozgur Yagan, Proffesor

STUDY CHAIR

Hitit University

Frequently Asked Questions

Who can join the NCT07546903 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Post Operative Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07546903 currently recruiting?

Yes, NCT07546903 is actively recruiting participants. Contact the research team at dr.matc92@gmail.com for enrollment information.

Where is the NCT07546903 trial being conducted?

This trial is being conducted at Çorum, Turkey (Türkiye).

Who is sponsoring the NCT07546903 clinical trial?

NCT07546903 is sponsored by Hitit University. The principal investigator is Ozgur Yagan, Proffesor at Hitit University. The trial plans to enroll 70 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology